Novel TRIP12 variants in two Lebanese patients with neurodevelopmental delay Authors: Simone Khalifeh, Nadine J Makhoul, Samah Trad, Sara Amro, Medhat Siddik, Joe Bedran, Rose-Mary Boustany Published: 2025 ABSTRACT AbstractBackgroundThe TRIP12 gene, encoding an E3 ligase involved in the ubiquitin-proteasome pathway, is implicated in Clark-Baraitser syndrome which causes neurodevelopmental delay and intellectual disability (ID). This study aims to present and characterize two distinct novel TRIP12 variants in two unrelated Lebanese children with neurodevelopmental delay.MethodsExome sequencing (ES) was performed, followed by in silico assessment of variant impact on protein structure. Clinical and molecular findings were described. Literature review was carried out on previously published TRIP12 variants.ResultsPatients demonstrated hypotonia, speech and motor delay. ES uncovered a paternally inherited missense variant in the TRIP12 gene (c.5905T > A nucleotide substitution) in patient 1, and a de novo indel variant causing an in-frame change (c.4532_4538delinsC) in patient 2. Affected amino acids in both variants were highly conserved, and structural analyses of mutant variants suggested altered TRIP12 protein structure. No phenotypic distinction emerged in comparison to 70 published TRIP12 variants.ConclusionThis study introduces the first Lebanese TRIP12 variants in developmentally delayed patients. It expands the genotypic spectrum of TRIP12-related neurodevelopmental disorders and underscores their variable expressivity.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12920-025-02299-x.Keywords: TRIP12 gene, Developmental delay, Exome sequencing, Genotype-phenotype correlation Background The Clark-Baraitser syndrome (MIM # 617752), described in 1987 manifests as intellectual disability in a mother and her two sons, obesity and dysmorphic facies [1]. Later genome sequencing on archived DNA determined that Clark-Baraitser syndrome resulted from autosomal dominant pathogenic mutations in the Thyroid Hormone Receptor Interactor 12 (TRIP12) gene (MIM # 604506) located on chromosome 2q36.3 [2]. This gene encodes an E3 ligase involved in the ubiquitin pathway responsible for protein sorting and degradation. Previous studies confirm TRIP12 participation in regulating multiple major biological processes [3]. The TRIP12 protein affects ubiquitination-mediated degradation of protein substrates, playing major roles in cell cycle progression, DNA damage repair, chromatin remodeling and cell differentiation [3]. Mutant TRIP12 is implicated in autism spectrum disorder (ASD), intellectual disability (ID), and cancers [3–5]. In this report, two unrelated Lebanese patients with neurodevelopmental delay and novel TRIP12 variants are described. This work adds to other TRIP12 gene molecular variations previously published, expanding diagnosis and perhaps impacting future therapeutic approaches. Research design and methods Subjects Two unrelated Lebanese patients diagnosed with TRIP12-related neurodevelopmental delay presented to the AUBMC Special Kids Clinic (ASKC). They underwent detailed clinical assessment and evaluation. A retrospective chart review provided information on clinical history, developmental milestones, physical and neurological examinations, neuroimaging and family history. Informed consent was obtained prior to genetic testing. Exome sequencing (ES) and Sanger sequencing DNA extraction and ES analysis were carried out at the Lebanese American University for patient 1, and at CENTOGENE (Rostock, Germany) for patient 2. Briefly, DNA was fragmented and targeted regions enriched according to manufacturer protocols. Generated libraries were sequenced on Illumina platform to obtain at least 20x coverage depth for > 98% of the targeted bases. An in-house bioinformatics pipeline, including read alignment to GRCh37/hg19 genome assembly, variant calling, annotation, and comprehensive variant filtering was applied. All variants with minor allele frequency (MAF) of less than 1% in gnomAD database, and disease-causing variants reported in HGMD, ClinVar and other databases were evaluated. Variants were classified according to ACMG/AMP guidelines. Identified TRIP12 variants were screened in parents by Sanger sequencing. TRIP12 variants analysis The identified TRIP12 variants were annotated using the GRCh37 genome assembly and RefSeq transcript NM_004238.3. In silico prediction analysis assessed variant effect on function/structure of protein. Thirty-four functional prediction tools were used with dbNSFP (v5.2a) database to assess missense variants and MutationTaster and MutPred-Indel to assess insertions/deletions. The evolutionary conservation of affected variant amino acids was assessed by Multiz alignments of 100 vertebrates, and base-wise conservation scores in 35 mammals with GERP and 100 vertebrates with PhyloP100way-vertebrate was calculated using the UCSC Genome Browser. GERP ranked scores range from − 12.36 to 6.17, and PhyloP from − 20.0 to 10.003, with a larger score indicating conserved sites. For the missense variant, DynaMut2 assessed impact on protein stability and flexibility reported as variation in Gibbs free energy (ΔΔG) (in Kcal/mol). Destabilizing effect is reported with ΔΔG < 0.0 kcal/mol and stabilizing effect with ΔΔG > 0.0 kcal/mol. For the indel variant, structural impact analysis used AlphaFold and AlphaMissense on the ChimeraX platform. Ranked protein conformations were expressed based on analyses of primary and secondary structures of proteins and comparison with wild-type TRIP12 protein with selection of the best-ranked model from the generated Predicted Aligned Error (PAE) plots for each conformation. Literature review and genotype-phenotype correlation TRIP12 variants in the literature using PubMed and Embase databases were identified. Relevant keyword used was “TRIP12 gene mutation” and search was limited to humans. After screening references, those purely related to cancer and obesity were excluded with focus on manuscripts linked to neurodevelopmental delay, intellectual disability, autism, motor delay and behavior disturbances. All reported variants were converted to transcript NM_004238.3 and annotated using genome assembly GRCh37. Previously reported cases of TRIP12 variants were compared with respect to the clinical and genetic data from the two Lebanese patients for genotype-phenotype correlation. Results Clinical characteristics Patient 1 is a 22-month-old daughter of non-consanguineous healthy parents. She was born by C-section at 38 weeks gestation with no perinatal complications. Her parents reported four infections in the four months prior to presentation with choking episodes and a brief resolved unexplained event (BRUE) witnessed on day one of life. At eight months of age, mild hypotonia, gross and fine motor delays were noted. She held her head at four months of age, sat without support at seven and a half months but was unable to raise her head when prone, bear weight, or roll over. She had unilateral reach and a raking grasp. She had good eye contact, smiled, recognized parents and strangers, spoke in monosyllables, babbled, enjoyed peek-a-boo but could not play games involving gestures or transfer objects. Physical exam, at age 8 months, revealed macrocephaly with frontal bossing and a head circumference of 46 cm (97th percentile). Length and weight were at 60th and 75th percentile, respectively. Deep tendon reflexes were normal, and mild hypotonia was detected. She was diagnosed with neurodevelopmental delay, primarily in the gross and fine motor domains. Magnetic Resonance Imaging (MRI) of the brain was requested but not carried out. Upon follow-up, she started cruising at 13 months. Bayley test at the age of 15 months proved extremely low motor scores and borderline cognitive, language and social-emotional scores. She had high-average general adaptive score. At 16 months, she was still unable to pull to stand or balance without falling. She was able to feed herself, point and began to partially roll over and transfer objects. At 20 months, she started walking, developed two-word speech, and began attending day care. Neither parent had neurodevelopmental delays. Patient 2 presented at age eight months with neurodevelopmental delay. He could coo but not babble. He elevated his head but could not sit without support. Grasp was present, but he could not transfer objects. He had difficulty chewing solid food due to orofacial muscles hypotonia. He was born full term by C-section for malposition with good Apgar scores (9 at 1 min and 10 at 5 min). Parents were non-consanguineous and had no history of neurodevelopmental delay. He had a normal older brother. On physical exam he had a broad nasal tip, a wide mouth and large ear lobes. Mild generalized hypotonia was noted. His head circumference was 43 cm (9th percentile for age). Weight was 8.5 kg (25%) and height was 72 cm (75%). Creatine phosphokinase blood level was 98 IU/L (normal for age). MRI of the brain at nine months confirmed adequate myelination with mild prominence of the cerebrospinal fluid (CSF) spaces in both frontal and temporal regions with a thinned corpus callosum (Fig. 1). Electromyography and nerve conduction were normal for age. Cardiac ultrasound was normal. The diagnosis of global neurodevelopmental delay was established and whole exome sequencing was done at one year of age. The patient started physical, occupational, and feeding/speech therapies. He attended daycare. He began walking at 19 months, eating non-mashed solid food by 1 year and 10 months of age. At 2 years and 10 months, he could produce two-word sentences. MRI brain images of patient 2 at nine months of age. Axial T2 (A), axial T2 FLAIR (B), and Sagittal (C) images show mild prominence of CSF spaces (arrow heads) and thin corpus callosum (line arrow) Genetic analysis ES analysis uncovered two heterozygous variants in TRIP12, not previously reported: a missense and an in-frame deletion-insertion both classified as variants of uncertain significance (VUS) (Table 1). Family pedigrees are depicted in Fig. 2. Table 1Clinical and molecular data of Lebanese individuals with TRIP12 variantsIndividual 1Individual 2GenderFemaleMaleAge in months2234Phenotypes Speech delay-+ Motor delay++ Hypotonia++ Dysmorphic faciesProminent foreheadBroad nasal tip, wide mouth, large earlobes, epicanthal folds, hypertelorism Macrocephaly + - Structural brain changes§+ Recurrent infection++ Variant (GRCh37)chr2-230632344-A-Tchr2-230653589-TTTGCTT-G InheritancePaternal De novo Variant TypeSNVDelins Molecular ConsequenceMissenseIn-frame Nucleotide change (NM_004238.3)c.5905T > Ac.4532_4538delinsC Amino acid change (NP_004229.1)p.(Ser1969Thr)p.(Lys1511_Asn1513delinsThr) Exon41/4131/41 gnomAD Allele frequency/dbSNP0.000007958/rs779019882Not foundFunction predictions Polyphen-2Pathogenic - SIFTBenign - MutPred2Gain of Sulfation at Y1968 (p = 0.02) - MutPred-Indel - Helix modification (p = 0.038105)Conservation scores PhyloP100way8.929.435 GERP_RS5.725.78§: unknown Clinical and molecular data of Lebanese individuals with TRIP12 variants gnomAD Allele frequency/ dbSNP 0.000007958/ rs779019882 §: unknown Pedigree of the two families, each with an affected individual carrying a TRIP12 variant In Patient 1, a single nucleotide substitution in the last exon of TRIP12 affecting the homologous E6AP C-terminus (HECT) domain of the protein (Fig. 3A) led to missense variant c.5905T > A (p.Ser1969Thr). This variant was inherited from a phenotypically unaffected father. In silico functional prediction of the variant showed discrepant results ranging from tolerant to damaging effects, yet functional analysis with MutPred2 suggested a significant probability of gain of sulfation with tyrosine at position 1968. Both substituted base and amino acid were highly conserved in 100 vertebrates (Table 1; Fig. 3B). Structural analysis indicated a possible destabilizing effect of the variant, potentially able to alter interactions between adjacent amino acids (Fig. 3C). The variant is classified as of uncertain significance, in accordance with the ACMG/AMP guidelines (PM2 + PP2). In silico effect prediction of identified TRIP12 variants. A: Schematic illustration of the TRIP12 protein (NP_004229.1) with black dots representing reported TRIP12 point mutations and variants in this study in red. B: TRIP12 protein sequence alignments from 10 species with affected amino acids highlighted by red boxes. C: Cartoon representations of wild-type and mutated TRIP12S1969T protein structures illustrated using DynaMut2 (based on AlphaFold predicted 3D structure: AF-Q14669-F1). Main interaction changes are highlighted with a yellow circle. Substitution of serine by threonine at position 1969 in TRIP12 is predicted to be slightly destabilizing to protein structure with a ΔΔG stability of −0.31 Kcal/mol. Hydrogen bonds (dotted red lines) with asparagine at position 1950 are lost in mutated protein, and polar interaction (not shown) with isoleucine at position 1973 replaced with a hydrophobic interaction (dotted green line). Dotted blue line: van der Waals forces; dotted pink lines: clashes. D: Cartoon representations of wild-type/mutated TRIP12K1511_N1513delinsT protein structures illustrated with ChimeraX. Substitution of amino acids lysine-alanine-asparagine at position 1511 to 1513 by a threonine significantly modifies helical structure of TRIP12 protein, resulting in severe conformational shifts in IDR, Ub region and HECT domain. E: Representation of TRIP12K1511_N1513delinsT shows 206 variant-induced clash sites in red. IDR: intrinsically disordered region, Ub: tandem ubiquitin-binding region, ARM: armadillo/β-catenin-like repeats, WWE: tryptophan-tryptophan-glutamate, HECT: homologous to E6AP C-terminus In Patient 2, a deletion of seven bases followed by an insertion led to an in-frame variant c.4532_4538delinsC (p.Lys1511_Asn1513delinsThr). Parental analysis revealed the variant as de novo. This variant was not identified in population databases, nor reported in clinical databases, and therefore is considered novel. The three affected amino acids lysine-alanine-asparagine (K-A-N) are highly conserved at position 1511–1513. Their replacement with threonine may significantly modify the helical structure of the TRIP12 protein (Table 1; Fig. 3D). The Intrinsically Disordered Region (IDR), HECT and the tandem ubiquitin-binding region within the ARM domain of the TRIP12 protein are predicted to undergo a severe conformational shift that could disrupt molecular stability by inducing 206 new clash sites (i.e., sites of ionic, covalent, or steric hindrance and interaction) not present in the wild-type counterpart protein (Fig. 3E). The variant is classified as likely pathogenic, in accordance with the ACMG/AMP guidelines (PM2 + PM4 + PM6). TRIP12 variant review The clinical and molecular characteristics of 86 individuals with 70 different TRIP12 variants reported in the literature [1–19] were reviewed and compared to the two patients described here (Supplementary Table). Affected individuals ranged in age from early childhood to late adulthood. Identified TRIP12 variants included frameshift, nonsense, missense and others with frameshift variants being the most common. Most variants were de novo. In this cohort, only four of 88 did not have intellectual disability, and were all under five years of age. Developmental delay, encompassing speech and/or motor delays, was observed in the majority of patients (87.5%), while dysmorphic facies were described in 79.5% (70/88). ASD was present in 40.9% (36/88) of patients, obesity in 28.4% (25/88), hypotonia in 22.7% (20/88), and seizures in 14.8% (13/88). Six (6.8%) patients presented with macrocephaly and another five with microcephaly. Discussion This report describes two patients presenting with developmental delay and facial dysmorphisms harboring TRIP12 variants. This adds to the growing body of literature on TRIP12-related neurodevelopmental disorders. Previous reports demonstrate common features and clinical heterogeneity. The most common features identified in earlier reports include moderate-to-severe mental retardation, behavioral problems, tall stature, obesity, severe macrocephaly, and typical facies of a large ‘square’ forehead, prominent supraorbital ridges, broad nasal tip, prominent lower lip and minor dental anomalies [6]. Later cohorts confirmed intellectual disability associated with speech, motor and global developmental delay as prevalent features. This is supported here. Patients in this study demonstrate the common feature of developmental delay, macrocephaly and typical dysmorphic facies. Formal evaluation them for presence of possible intellectual disability was not possible due to young ages at presentation. A more recent case series of 38 individuals with TRIP12 variants objectified characteristic facial traits through GestaltMatcher image analysis based on deep-learning algorithms in order to define a TRIP12 gestalt. The TRIP12 facial gestalt they constructed is characterized by deep-set eyes, a broad nasal tip, a wide mouth and low-set ears with large earlobes. These findings suggest a distinct TRIP12 facial appearance [7]. While dysmorphic facies are seen in a majority of cases, non-syndromic cases are also reported in the literature [8] and were identified here. Patient 1 demonstrated only a prominent forehead without evident characteristic facial features but those could evolve with age. Obesity, which was initially thought to be a defining feature of the syndrome, was present in approximately only half of cases [7] and in a lower proportion here (28.4%). Seizures were reported in a minority of cases (~ 20%) [7] and in 14.8% here. The TRIP12 gene was initially implicated in ASD by O’Roak et al. in 2014. The occurrence of ASD in patients with TRIP12 variants is 40.9%. The two patients in this study did not exhibit symptoms of autism, obesity, or seizure disorder, but these should be monitored as they grow. No evident phenotypic differences were observed in the reported TRIP12 variant types described here (Supplementary Table) [1, 2, 4, 5, 7–19]. Aerden et al. (2023) suggest a more severe phenotype in missense variants after comparing 35 TRIP12 variants, 10 of which were missense [7]. This was based on more severe regression, and occurrence of ASD, epilepsy and intellectual disability in this subgroup. Due to limited phenotypic details in previous reports, this observation remains difficult to validate. Thorough review of published cases identified two recurrent and four familial genetic variants in individuals who exhibited slight differences in phenotypic expression (Supplementary Table). Previous studies highlight incomplete penetrance and variable expressivity in familial variants of TRIP12. Nobakht et al. (2025) describe a familial TRIP12 variant in which the father exhibited a milder phenotype than his children. He lacked developmental delay, dysmorphic facies or other anomalies observed in affected offspring [19]. These differences may reflect additional genetic or environmental factors at play, as suggested by Aerden et al. (2023) [7]. In this study, patient 1 had symptoms consistent with those reported for pathogenic TRIP12 variants. Her father, however, did not exhibit any speech, motor, or cognitive delays, despite carrying the same variant. He has no dysmorphic features and had completed higher education. Potential explanations include mosaicism in the father, influence of modifier genes, or the inherent variable expressivity of TRIP12 variants [2]. Incomplete penetrance is a characteristic of pathogenic variants in which carriers do not manifest the associated phenotype [20]. Similar observations were previously reported describing TRIP12 variants inherited from healthy parents. Bramswig et al. (2017) described a male patient who inherited missense variant from a healthy mother; he presented with mild developmental delay, ASD, ID, mild dysmorphic facies, and seizures [8]. Özaslan et al. (2021) reported a girl with ASD, ID, speech delay, dysmorphic facies, and hypotonia, with a duplication of the TRIP12 gene inherited from a healthy father [14]. These examples support the notion that TRIP12 variants may exhibit incomplete penetrance. A limitation of this study is the absence of functional studies of the TRIP12 variants. This could provide additional evidence supporting their pathogenicity. In addition, the lack of detailed phenotypic description and cognitive assessment in some previous reports limited the ability to draw clear phenotype-genotype correlations for this disorder. Nevertheless, this study underscores the challenge of interpreting the term ‘variant of uncertain significance’ in clinical practice. Physicians should carefully address their patients’ genetic results to avoid missing potential variants that may explain the condition and guide management. Recognizing incomplete penetrance is critical for genetic counseling as a seemingly healthy parent may transmit a pathogenic variant to offspring who then manifest clinical features. Conclusion This study contributes to the evolving and expanded genotype-phenotype profile of TRIP12 mutations by delineating two novel variants in unrelated Lebanese patients. Given that TRIP12 deficiency is rare, with additional cases likely to be identified in the future, further investigations are essential to enhance diagnosis and potentially help elucidate pathogenesis. Supplementary Information Supplementary Material 1. Acknowledgements The authors would like to thank the patients and their families, as well as the nursing and the medical teams who participated in their care. We also wish to thank Ms. Hala Maacaron for her administrative support. Abbreviations armadillo/β-catenin-like repeats Autism Spectrum Disorder American University of Beirut Medical Center AUBMC Special Kids Clinic Brief resolved unexplained event Cerebrospinal fluid Exome sequencing Homologous E6AP C-terminus Intellectual disability intrinsically disordered region Magnetic Resonance Imaging Predicted Aligned Error tandem ubiquitin-binding region Variants of Uncertain Significance tryptophan-tryptophan-glutamate Authors’ contributions **SK** is the patient clinician who wrote the initial draft, reviewed the literature, summarizing the TRIP12 variants in the supplementary table and edited the multiple drafts of this manuscript. **NJM** assisted in genetic/molecular description of variants, analysis of databases, generating structural prediction, and in the writing of the manuscript. **ST** contributed to the clinical and molecular literature review and in the writing of the manuscript. **SA and MS** reviewed medical files of patients, summarized the clinical information, and contributed to literature review. **JB** assisted in generating structural prediction. **RMB** supervised the neurogenetics team unifying clinical and genetics analyses together, edited the manuscript guiding the collaborative efforts and the finalization of the manuscript. Funding The authors received no financial support to conduct this work. Data availability All data generated or analysed during this study are included in this published article and its supplementary information file. The two *TRIP12* variants reported in this article were deposited into ClinVar with accession numbers: SCV006550825 and SCV006550826. Declarations Ethics approval and consent to participate Our study adhered to the principles of Declaration of Helsinki. Informed consent to participate was obtained from the parents or legal guardians of any participant under the legal age. All the data of the two participants were de-identified. Institutional Review Board (IRB) Ethical approval is not applicable here. Consent for publication Written informed consent was obtained from parents of participants, who are minors, for the publication of personal or clinical details along with any identifying images in this study. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Simone Khalifeh, Email: sk205@aub.edu.lb. Rose-Mary Boustany, Email: rb50@aub.edu.lb. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement All data generated or analysed during this study are included in this published article and its supplementary information file. The two *TRIP12* variants reported in this article were deposited into ClinVar with accession numbers: SCV006550825 and SCV006550826.